Free Trial

Voyager Therapeutics (VYGR) Competitors

Voyager Therapeutics logo
$5.75 +0.06 (+1.05%)
(As of 12/20/2024 05:17 PM ET)

VYGR vs. OCUL, MESO, TVTX, NTLA, PRAX, ARVN, DAWN, ARDX, SYRE, and SPRY

Should you be buying Voyager Therapeutics stock or one of its competitors? The main competitors of Voyager Therapeutics include Ocular Therapeutix (OCUL), Mesoblast (MESO), Travere Therapeutics (TVTX), Intellia Therapeutics (NTLA), Praxis Precision Medicines (PRAX), Arvinas (ARVN), Day One Biopharmaceuticals (DAWN), Ardelyx (ARDX), Spyre Therapeutics (SYRE), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry.

Voyager Therapeutics vs.

Voyager Therapeutics (NASDAQ:VYGR) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, community ranking, risk, media sentiment and institutional ownership.

Voyager Therapeutics currently has a consensus target price of $17.00, suggesting a potential upside of 195.65%. Ocular Therapeutix has a consensus target price of $16.71, suggesting a potential upside of 96.64%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Voyager Therapeutics is more favorable than Ocular Therapeutix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Voyager Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11
Ocular Therapeutix
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 4.5% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Voyager Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.

Ocular Therapeutix received 45 more outperform votes than Voyager Therapeutics when rated by MarketBeat users. Likewise, 70.14% of users gave Ocular Therapeutix an outperform vote while only 67.59% of users gave Voyager Therapeutics an outperform vote.

CompanyUnderperformOutperform
Voyager TherapeuticsOutperform Votes
392
67.59%
Underperform Votes
188
32.41%
Ocular TherapeutixOutperform Votes
437
70.14%
Underperform Votes
186
29.86%

Voyager Therapeutics has a net margin of 15.80% compared to Ocular Therapeutix's net margin of -283.74%. Voyager Therapeutics' return on equity of 8.33% beat Ocular Therapeutix's return on equity.

Company Net Margins Return on Equity Return on Assets
Voyager Therapeutics15.80% 8.33% 6.15%
Ocular Therapeutix -283.74%-45.18%-30.87%

In the previous week, Voyager Therapeutics had 1 more articles in the media than Ocular Therapeutix. MarketBeat recorded 3 mentions for Voyager Therapeutics and 2 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.72 beat Voyager Therapeutics' score of 0.50 indicating that Ocular Therapeutix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Voyager Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ocular Therapeutix
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Voyager Therapeutics has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Voyager Therapeutics$163.78M1.92$132.33M$0.718.10
Ocular Therapeutix$61.44M21.75-$80.74M-$1.32-6.44

Summary

Voyager Therapeutics beats Ocular Therapeutix on 13 of the 19 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VYGR vs. The Competition

MetricVoyager TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$314.10M$2.94B$5.12B$9.07B
Dividend YieldN/A1.90%4.91%4.22%
P/E Ratio8.1046.7391.3417.19
Price / Sales1.92411.851,117.70116.80
Price / Cash2.07182.1042.6437.86
Price / Book1.073.894.794.78
Net Income$132.33M-$42.21M$120.07M$225.60M
7 Day Performance-8.29%-2.14%-1.90%-1.23%
1 Month Performance5.89%4.21%11.45%3.37%
1 Year Performance-29.45%18.40%30.63%16.58%

Voyager Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VYGR
Voyager Therapeutics
4.6047 of 5 stars
$5.75
+1.1%
$17.00
+195.7%
-27.6%$314.10M$163.78M8.10100
OCUL
Ocular Therapeutix
3.6461 of 5 stars
$9.03
+3.9%
$16.71
+85.1%
+116.8%$1.42B$58.44M0.00267Positive News
MESO
Mesoblast
1.0466 of 5 stars
$12.16
+3.4%
$11.50
-5.4%
+590.1%$1.39B$5.90M0.0080Analyst Forecast
Options Volume
News Coverage
Gap Down
TVTX
Travere Therapeutics
2.7815 of 5 stars
$17.65
+1.9%
$22.62
+28.1%
+106.0%$1.38B$145.24M-3.81460Positive News
NTLA
Intellia Therapeutics
4.1284 of 5 stars
$13.50
+4.7%
$54.94
+306.9%
-58.9%$1.37B$36.28M-2.37600
PRAX
Praxis Precision Medicines
2.4059 of 5 stars
$71.98
+2.6%
$146.33
+103.3%
+323.0%$1.34B$2.45M-7.06110Gap Down
High Trading Volume
ARVN
Arvinas
2.0323 of 5 stars
$19.35
-0.8%
$63.50
+228.2%
-49.3%$1.33B$78.50M-4.18445
DAWN
Day One Biopharmaceuticals
1.6299 of 5 stars
$12.74
-0.1%
$35.71
+180.3%
-7.7%$1.28B$101.95M-12.3860Positive News
ARDX
Ardelyx
3.6852 of 5 stars
$5.39
+3.3%
$10.42
+93.3%
-18.9%$1.28B$251.85M-17.80267
SYRE
Spyre Therapeutics
1.77 of 5 stars
$24.65
+2.2%
$51.50
+108.9%
+53.4%$1.27B$890,000.00-3.23100
SPRY
ARS Pharmaceuticals
2.9441 of 5 stars
$12.27
+3.1%
$24.00
+95.6%
+121.8%$1.19B$30,000.00-23.3390Insider Trade
News Coverage

Related Companies and Tools


This page (NASDAQ:VYGR) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners